Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis-Reference-Cited by-同舟云学术

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

Published:2018-11 Issue: Volume:104 Page:188-194
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Campbell Matthew T.^ORCID,Bilen Mehmet A.,Shah Amishi Y.,Lemke Emily,Jonasch E.,Venkatesan A.M.,Altinmakas E.,Duran C.,Msaouel Pavlos^ORCID,Tannir N.M.

Funder

MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Renal-cell carcinoma;Cohen;N Engl J Med,2005

2. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN);Armstrong;J Clin Oncol,2015

3. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): a multicenter randomized phase 2 trial;Tannir;J Clin Oncol,2014

4. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;Yakes;Mol Canc Therapeut,2011

5. Cabozantinib versus everolimus in advanced renal-cell carcinoma;Choueiri;N Engl J Med,2015

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy;Japanese Journal of Clinical Oncology;2024-08-23

2. Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy;Kidney Cancer;2024-08-02

3. Papillary Renal Cell Carcinoma: Current Evidence and Future Directions;Kidney Cancer;2024-05-07

4. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review;Medicina;2024-02-26

5. Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients;Therapeutic Advances in Urology;2024-01